Drug
RBS2418
RBS2418 is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
recruiting375%
unknown125%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_2
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
NCT07175441
recruitingphase_2
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
NCT06824064
recruitingphase_1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05270213
unknown
Expanded Access RBS2418 Treatment
NCT05683470
Clinical Trials (4)
Showing 4 of 4 trials
NCT07175441Phase 2
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
NCT06824064Phase 2
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
NCT05270213Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05683470
Expanded Access RBS2418 Treatment
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4